Esteve Pharmaceuticals has acquired the exclusive rights to market Inbrija dry powder levodopa in Spain and expects to launch the product there by the end of 2022, according to Acorda Therapeutics. Esteve will pay Acorda “a significant double-digit percent of the selling price” for Acorda to supply the product.
The Inbrija DPI was approved in Europe for the treatment of OFF periods in Parkinson’s disease in 2019. In the US, the FDA approved Inbrija in December 2018, and Acorda launched the DPI in February 2019. In January 2021, Acorda sold the Inbrija manufacturing facility in Massachusetts to Catalent, with Catalent taking over production of the inhaled levodopa.
Acorda President and CEO Ron Cohen commented, “We are delighted to enter a partnership with Esteve to make Inbrija available in Spain. This is great news for people with Parkinson’s in Spain who are in need of therapies to treat their OFF periods. Esteve has an impressive track record of successfully commercializing pharmaceuticals in Europe for neurological and other indications. We are also in active discussions with additional companies for the rights to Inbrija in other countries in Europe and the rest of the world.”
Read the Acorda Therapeutics press release.
